CliffBio
small molecule

QSYMIA

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

Loss of exclusivityJune 2029latest FDA-listed patent expiry
CompanyVivus, Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameQSYMIA
Active ingredientPHENTERMINE HYDROCHLORIDE; TOPIRAMATE
StrengthEQ 7.5MG BASE;46MG
Dosage formCAPSULE, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2012
Marketing statusRX

Listed patents

PatentExpiresType
8580299June 2029use U-3399
8580298May 2029product
9011906June 2028use U-3398
8895057June 2028use U-3398
9011905June 2028product
8895058June 2028product

Regulatory exclusivity

CodeExpires
M-308September 2027

More from Vivus, Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

QSYMIA patent cliff — loss of exclusivity June 2029 | CliffBio